Establishment and duration of protective immunity against SARS-CoV-2, in relation to severity of SARS-CoV-2 infection

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.043E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $494,303.11
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principle Investigator

    Pending
  • Research Location

    Netherlands, Europe
  • Lead Research Institution

    Sanquin Research
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    Gender

  • Study Subject

    Non-Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Project description In most people, a specific immune response can be demonstrated after a COVID-19 infection. However, it is not known how long and how well this immune response protects against re-infection. This can be investigated at Sanquin because blood is regularly collected from 300,000 blood donors, some of which is also stored for two years. Research For donors who have had COVID-19 disease - from asymptomatic to seriously ill - the course of COVID-19 antibodies in the serum and (in a subgroup) the memory cells will be analyzed for two years. To what extent an immune response protects against re-infection is prospectively investigated in 2000 antibody positive donors. In addition, all people who are tested positive for COVID19-PCR from September 2020 will be checked to see whether they are blood donors. The plasma of these people, which was frozen around July 2020, will then be tested. Expected outcomes If a previous infection protects, it is expected that much fewer anti-COVID-19 antibodies are found in the COVID-19-PCR positive group than in the control group.